A team at the University Medical Center Mainz believes it has built a bridge across that gap. In a new study published in Frontiers in Lupus, researchers led by Matthias Dreher and Andreas Schwarting report an evaluation of the Mainz Lupus Score, or MLS, a pragmatic clinical support tool designed not to replace established disease activity indices but to translate their logic into a format that any physician can apply during a routine outpatient visit. The score was developed at the Mainz Lupus Center, a tertiary referral facility caring for roughly 700 patients with SLE and related autoimmune diseases, over approximately one year of iterative consensus rounds involving both senior lupus specialists and junior physicians. The explicit goal was to maximize agreement between therapeutic decisions made by experts guided by current recommendations and decisions reached by less-experienced clinicians armed only with the MLS.

The architecture of the score is deliberately simple. It comprises four items, each capturing a dimension that matters for therapy adjustment. The first asks whether any new lupus-specific symptoms have appeared within the preceding two to four weeks, accepting all symptoms included in the SLE Disease Activity Index and the European Consensus Lupus Activity Measurement Index; a simple yes scores 5 points, a no scores 0, with no differentiation by intensity or organ system, because every new symptom signals rising disease activity. The second item captures the patient’s subjective quality of life using a visual analog scale from 0, meaning good, to 10, meaning poor, weighted as 0 points for scores of 0 to 3, 1 point for 4 to 6, and 3 points for 7 to 10. The third item grades laboratory findings: normal results score 0, stable abnormalities score 1, and newly occurring or aggravated abnormalities score 3. The parameters range from nonspecific changes such as anemia, lymphopenia, thrombocytopenia, and elevated erythrocyte sedimentation rate to more specific markers including low complement levels C3, C4, and CH50, elevated antinuclear antibodies such as dsDNA, Sm, and U1-RNP, and urinalysis findings like proteinuria and active sediment that may signal kidney involvement, all aligned with the 2019 EULAR/ACR classification criteria for SLE.

The fourth item addresses cumulative organ damage, including kidney involvement, central nervous system complications, and cardiac deterioration from cardiovascular disease. No organ involvement earns 0 points, stable damage identical to the previous SLICC assessment earns 1 point, and exacerbated damage earns 5 points, a comparison that requires reference to earlier examinations. Therapy-related adverse events demand immediate treatment adjustment regardless of the score. The current prednisolone dose is recorded alongside the score to characterize the activity state. Patients are then classified using the DORIS remission definitions and the lupus low disease activity state framework: remission requires a SLEDAI of 0 with prednisolone at or below 5 milligrams per day and no immunosuppressants; DORIS remission on treatment allows stable antimalarials, immunosuppressants, and biologics; LLDAS requires a SLEDAI below 4, prednisolone at or below 7.5 milligrams per day, and no activity in major organ systems; everything else counts as active disease. Notably, the developers chose not to include the physician global assessment, a component of the original consensus definitions, precisely because it demands substantial experience and would therefore undermine the score’s accessibility to novices.

The resulting total maps onto three therapeutic pathways. A score of 0 to 2 points recommends no change in therapy. A score of 3 to 4 marks a borderline zone in which therapy should be reviewed and potentially adjusted, guided by supplementary assessments such as the Work Ability Index and the Fatigue Severity Scale. A score of 5 to 16 clearly recommends therapy escalation, defined broadly to include medication changes as well as supportive therapies depending on the manifestation. The entire scoring process takes only a few minutes, while the subjective questionnaires are ideally completed by patients before the visit.

To test the tool, the researchers analyzed data from 458 SLE patients treated at Mainz since the score’s introduction in 2016. The longitudinal sub-cohort comprised 93 patients with at least three consecutive visits, generating 422 visits in total, averaging 4.5 visits per patient. The full cohort had a mean age of 42.3 years, was 88 percent female, and showed a mean disease duration of 7.5 years with a mean SLEDAI of 4.4, indicating moderate disease activity. The sub-cohort was slightly older at 46.9 years, 92.5 percent female, with a longer disease duration of 13.8 years. Major organ involvement included the kidney in 65 percent of patients, skin in 50 percent, and joints in 35 percent. Across all 422 visits, 60 percent of MLS results fell in the lowest stage, 9.5 percent in the borderline stage, and 30.5 percent in the escalation stage, while roughly 80 percent of visits found patients in SLEDAI-defined remission.

The statistical performance was convincing on the objective front. Using Spearman rank correlations and Kruskal-Wallis tests, the team found significant correlations between the MLS and the established indices: r = 0.403 for SLEDAI, r = 0.427 for the SLICC damage index, and r = 0.537 for ECLAM, all with p values below 0.0001. The MLS also correlated significantly with DORIS remission status and with prednisolone dose, both at p < 0.0001, confirming its alignment with treat-to-target goals. Associations with patient-reported outcomes were more nuanced. The correlation with the Beck Depression Inventory was modest at r = 0.141, and the Work Ability Index showed a significant Kruskal-Wallis statistic of 20.58, but the Fatigue Severity Scale for motor and cognitive functions showed no significant correlation at r = 0.079. Strikingly, SLEDAI itself showed no significant association with any of the three subjective measures, underscoring the developers’ central argument: fatigue and impaired well-being, which affect nearly half of the cohort at severe levels by the FSMC, are largely invisible to conventional activity indices yet contribute enormously to disease burden.

Perhaps the most clinically consequential finding came from the head-to-head comparison with experienced physicians. When the change in remission status from visit to visit was scored on an ordinal scale, where moving from LLDAS to DORIS remission counted as an improvement of one level and sliding from DORIS remission to active disease counted as a deterioration of two, there was no significant difference between therapy decisions guided by the MLS and those made by medical doctors, with a p value of 0.9398 across 327 visits. In other words, a structured four-item checklist reproduced the judgment of lupus experts without requiring their years of accumulated pattern recognition. The authors are careful to note that this does not constitute a formal psychometric derivation and validation of a new disease activity index; it is an evaluation of a decision-support instrument in a large real-world cohort, and the score’s pragmatic weighting was refined through repeated use rather than statistical modeling.

The study acknowledges its limitations candidly. Categorizing continuous variables inevitably discards information, and the rule that any new symptom, regardless of severity, may justify escalation could theoretically promote overtreatment, while the coarse grading risks undertreatment in subtle flares. The data come from a single center, though comparisons with the Swiss SLE Cohort Study and the Canadian 1,000 Faces of Lupus cohort of up to 1,528 patients reveal closely matching demographic and clinical characteristics, supporting the representativeness of the Mainz sample. No distinction was made between newly diagnosed and long-standing patients. The work was supported by a grant from GSK, which was given the opportunity to review a draft for factual accuracy, and several authors disclosed honoraria and research grants from pharmaceutical companies including GSK, AstraZeneca, and Novartis, though the authors retain sole responsibility for the content.

What emerges is a tool that balances objectivity with the patient’s voice at a moment when shared decision-making has become a central principle of lupus care. Impaired quality of life does not always demand a pharmacological change, the authors note, but it can prompt referral to psychotherapy, nutritional counseling, physiotherapy, or exercise therapy, interventions that conventional activity scores would never trigger. The team recommends broader multi-center validation to refine the weighting and test generalizability across different healthcare systems. If those studies confirm the Mainz results, the MLS could become a template for how complex autoimmune medicine is democratized: distilling expert consensus into a few minutes of structured assessment, and ensuring that the patient’s own report of fatigue and well-being finally counts as data.

Subject of Research: Validation of the Mainz Lupus Score as a clinical decision-support tool for assessing disease activity and guiding therapy in systemic lupus erythematosus

Article Title: Evaluation of the Mainz Lupus Score: a clinical support tool for managing Systemic Lupus Erythematosus

Article References: Dreher, M., Amon, J., Boedecker-Lips, S. C., Weinmann-Menke, J., Weinmann, A., & Schwarting, A. (2026). Evaluation of the Mainz Lupus Score: a clinical support tool for managing Systemic Lupus Erythematosus. Frontiers in Lupus, 4, Article 1873891. https://doi.org/10.3389/flupu.2026.1873891

Image Credits: AI Generated

DOI: 10.3389/flupu.2026.1873891

Keywords: systemic lupus erythematosus, Mainz Lupus Score, SLEDAI, ECLAM, SLICC, patient-reported outcomes, treat-to-target, remission, autoimmune disease, clinical decision support, rheumatology, quality of life